Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Liver Transplant
Findings from Astellas Pharma US, Inc. broaden understanding of liver transplant
May 16th, 2008
Scientists discuss in 'First clinical experience with the new once-daily formulation of tacrolimus' new findings in liver transplant. "Once-daily tacrolimus is a new oral formulation of the established immunosuppressive agent tacrolimus (Prograf, Astellas Pharma US, Inc., Deerfield, IL), which is administered twice daily. It has been approved in the European Union for prophylaxis of rejection in liver and kidney transplant recipients, where it is registered as Advagraf, and in Canada for the prophylaxis of rejection in kidney transplant recipients, and is currently under review in the United States and Japan," investigators in the United States report. "Studies with...
Source: Health Business Week (2008-05-16)
|
